Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

1.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G.

Diabetes Obes Metab. 2013 Apr;15(4):372-82. doi: 10.1111/dom.12054. Epub 2013 Jan 24.

PMID:
23279307
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.

Nisly SA, Kolanczyk DM, Walton AM.

Am J Health Syst Pharm. 2013 Feb 15;70(4):311-9. doi: 10.2146/ajhp110514. Review.

PMID:
23370138
[PubMed - indexed for MEDLINE]
3.

Canagliflozin: a novel treatment option for type 2 diabetes.

Dietrich E, Powell J, Taylor JR.

Drug Des Devel Ther. 2013 Nov 22;7:1399-408. doi: 10.2147/DDDT.S48937. eCollection 2013. Review.

PMID:
24285921
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.

Lamos EM, Younk LM, Davis SN.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. Review.

PMID:
23590413
[PubMed - indexed for MEDLINE]
5.

Canagliflozin for the treatment of type 2 diabetes.

Babu A.

Drugs Today (Barc). 2013 Jun;49(6):363-76. doi: 10.1358/dot.2013.49.6.1965099. Review.

PMID:
23807940
[PubMed - indexed for MEDLINE]
6.

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Plosker GL.

Drugs. 2012 Dec 3;72(17):2289-312. doi: 10.2165/11209910-000000000-00000. Review.

PMID:
23170914
[PubMed - indexed for MEDLINE]
7.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Kurosaki E, Ogasawara H.

Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Review.

PMID:
23563279
[PubMed - indexed for MEDLINE]
8.

Dapagliflozin: a review on efficacy, clinical effectiveness and safety.

Paisley AN, Yadav R, Younis N, Rao-Balakrishna P, Soran H.

Expert Opin Investig Drugs. 2013 Jan;22(1):131-40. doi: 10.1517/13543784.2013.740009. Epub 2012 Nov 6. Review. Erratum in: Expert Opin Investig Drugs. 2013 Jul;22(7):939. Paisley, Angela J [corrected to Paisley, Angela N].

PMID:
23127205
[PubMed - indexed for MEDLINE]
9.

[The cutting-edge of medicine; novel therapeutic agents for the treatment of diabetes sodium-glucose co-transporter (SGLT) 2 inhibitors].

Sugimoto T, Kashiwagi A.

Nihon Naika Gakkai Zasshi. 2013 Jun 10;102(6):1474-83. Review. Japanese. No abstract available.

PMID:
23947218
[PubMed - indexed for MEDLINE]
10.

Sweet & low: new treatment for diabetes that may reduce blood pressure.

Cohen DL, Townsend RR.

J Clin Hypertens (Greenwich). 2013 May;15(5):305. doi: 10.1111/jch.12092. Epub 2013 Apr 1. Review. No abstract available.

PMID:
23614842
[PubMed - indexed for MEDLINE]
11.

SGLT-2 inhibitors and their potential in the treatment of diabetes.

Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ.

Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. Review.

PMID:
24348059
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk